A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab

The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total patho...

Full description

Bibliographic Details
Main Authors: Charlie Yang, Raida Khwaja, Patricia Tang, Nancy Nixon, Karen King, Sasha Lupichuk
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Current Oncology
Subjects:
trastuzumab
biosimilar
MYL-1401O
HER2+
breast cancer
early stage
Online Access:https://www.mdpi.com/1718-7729/29/6/337

Internet

https://www.mdpi.com/1718-7729/29/6/337

Similar Items